首页> 外文期刊>The Lancet Global Health >Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine versus single screening and treatment for the control of malaria in pregnancy in Papua, Indonesia: a provider perspective analysis from a cluster-randomised trial
【24h】

Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine versus single screening and treatment for the control of malaria in pregnancy in Papua, Indonesia: a provider perspective analysis from a cluster-randomised trial

机译:与二氢氨基氨苄蛋白 - 哌喹 - 哌喹 - 哌喹对巴布亚,印度尼西亚妊娠期疟疾治疗疟疾治疗的成本效益 - 妊娠期疟疾治疗:集群随机试验的提供商透视分析

获取原文
           

摘要

Background Malaria infection during pregnancy is associated with serious adverse maternal and birth outcomes. A randomised controlled trial in Papua, Indonesia, comparing the efficacy of intermittent preventive treatment with dihydroartemisinin-piperaquine with the current strategy of single screening and treatment showed that intermittent preventive treatment is a promising alternative treatment for the reduction of malaria in pregnancy. We aimed to estimate the incremental cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine compared with single screening and treatment with dihydroartemisinin-piperaquine. Methods We did a provider perspective analysis. A decision tree model was analysed from a health provider perspective over a lifetime horizon. Model parameters were used in deterministic and probabilistic sensitivity analyses. Simulations were run in hypothetical cohorts of 1000 women who received intermittent preventive treatment or single screening and treatment. Disability-adjusted life-years (DALYs) for fetal loss or neonatal death, low birthweight, moderate or severe maternal anaemia, and clinical malaria were calculated from trial data and cost estimates in 2016 US dollars from observational studies, health facility costings and public procurement databases. The main outcome measure was the incremental cost per DALY averted. Findings Relative to single screening and treatment, intermittent preventive treatment resulted in an incremental cost of US$5657 (95% CI 1827 to 9448) and 107·4 incremental DALYs averted (–719·7 to 904·1) per 1000 women; the average incremental cost-effectiveness ratio was $53 per DALY averted. Interpretation Intermittent preventive treatment with dihydroartemisinin-piperaquine offers a cost-effective alternative to single screening and treatment for the prevention of the adverse effects of malaria infection in pregnancy in the context of the moderate malaria transmission setting of Papua. The higher cost of intermittent preventive treatment was driven by monthly administration, as compared with single-administration single screening and treatment. However, acceptability and feasibility considerations will also be needed to inform decision making. Funding Medical Research Council, Department for International Development, and Wellcome Trust.
机译:妊娠期间的背景疟疾感染与严重不利的孕产妇和出生结果有关。巴布亚,印度尼西亚的随机对照试验,比较与二氢氨基氨苄蛋白 - 稻瘟病的间歇性预防治疗的功效与单筛选和治疗的目前策略表明,间歇性预防治疗是对妊娠期疟疾减少的有希望的替代治疗方法。我们的旨在估算与二氢氨基氨苄蛋白 - 哌啶蛋白与二氢氨基蛋白蛋白蛋白 - 哌啶蛋白蛋白的间歇预防性治疗的增量成本效益。方法我们做了提供商的透视分析。在寿命范围内从健康提供者的角度分析了决策树模型。模型参数用于确定性和概率敏感性分析。仿真在1000名接受间歇性预防治疗或单一筛查和治疗的女性的假设队列中运行。胎儿丧失或新生儿死亡,低出生体重,中度或严重孕妇贫血和临床疟疾的残疾寿命年(DALYs)是根据从观察研究,卫生机构花费和公共采购的试验数据和成本估算计算的数据库。主要结果措施是每达利避免的增量成本。相对于单筛选和治疗的发现,间歇预防性治疗导致增量成本为5657美元(95%CI 1827至9448),107·4个增量DALYS避免(-719·7至904·1)每1000名女性;平均增量成本效益比为每达利避免53美元。解释与二氢氨基氨苄蛋白 - 哌啶素蛋白的间歇性预防治疗为单次筛选和治疗具有成本效益的替代方法,用于预防疟疾感染在妊娠的中度疟疾传输设置中疟疾感染的不利影响。与单次施用单筛选和治疗相比,每月给药驱动间歇性预防治疗成本较高。但是,还需要可接受性和可行性考虑来告知决策。资助医学研究委员会,国际发展部和惠康信托。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号